Annexon, Inc. Common Stock (ANNX)
Annexon, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases. It specializes in targeting the complement system to address conditions such as Alzheimer’s disease, multiple sclerosis, and other immune-related disorders. The company's approach involves creating monoclonal antibodies that modulate the immune response to prevent cellular damage.
Company News
Annexon completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a potential treatment for dry age-related macular degeneration with geographic atrophy. The trial aims to demonstrate vision preservation and is expected to report topline data in the second half of 2026.
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply during Wednesday’s session after the company reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market est...
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.